Heghine Khachatryan։ Age-Adjusted D-Dimer Thresholds for Safer and Smarter VTE Rule-Out
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared RPTH’s post on LinkedIn:
”A very important and practical review published in the RPTH Journal highlights a concept that deserves wider clinical attention: age-adjusted D-dimer thresholds.
D-dimer levels naturally increase with age, meaning that the traditional fixed cut-off may lead to false positives and unnecessary imaging, especially in older patients.
Using age-adjusted D-dimer values (Age × 10 µg/L for patients >50 years) helps maintain safety in ruling out VTE while reducing unnecessary CT scans, radiation exposure, and healthcare costs.
This is a clear example of how smarter interpretation of existing diagnostic tests can significantly improve clinical decision-making.”
RPTH Journal shared a post on LinkedIn about a recent article by Tayssir Fatah et al, published in RPTH Journal:
”Is the D-dimer cut-off we use every day actually outdated?
We order D-dimer constantly to rule out VTE. But here’s the problem: D-dimer naturally rises with age.
That means the standard cut-off becomes less specific every year a patient gets older, leading to more false positives and more unnecessary CT scans.
This RPTH review revisits one of the most practical changes in thrombosis diagnostics:
Age-adjusted D-dimer thresholds.
The concept is simple:
For patients >50 years, use Age × 10 μg/L instead of a fixed cut-off.
Why this matters
- It maintains safety for ruling out VTE.
- It reduces unnecessary imaging.
- It cuts radiation exposure and healthcare costs.
- It improves emergency department workflow and patient experience.
Yet despite strong evidence, adoption is still inconsistent worldwide.
So the real question becomes:
- Why hasn’t this become universal practice yet?
- Do your local protocols use age-adjusted D-dimer?
- What barriers still exist in implementation?
Sometimes the most impactful innovation isn’t a new drug, it’s using existing tests smarter.”
Title: Raising the D-dimer bar: a narrative review of the age-adjusted D-dimer threshold
Authors: Tayssir Fatah, Judith Catella, Christophe Nougier, Hamdi Rezigue
Read Full Article on RPTH Journal
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH
-
Sep 25, 2026, 05:24Isabelle Mahé: Reduced-Dose Apixaban in Extended CAT Treatment
-
Sep 25, 2026, 05:15Maria Cherska: High Cholesterol Isn’t Always Diet or Lifestyle – Sometimes It’s Genetic
-
Sep 25, 2026, 05:07Nancy Braithwaite: BBTS Specialist Certificate in Transfusion Science Practice
-
Sep 24, 2026, 18:43Hugh Nguyen: Honored to Accept the Friend of Singapore Red Cross Award
-
Sep 24, 2026, 18:42Titilope Fasipe: Proud to Support American Society of Hematology’s SCD Initiative